Contineum Therapeutics, Inc. Class A (CTNM)

Contineum Therapeutics announced a proposed public offering of $75.0 million in December 2025. In March 2026, the company reported its fourth-quarter 2025 financial results and affirmed key clinical development milestones. Millennium Management LLC reported a 5.1% stake in April 2026. Contineum Therapeutics reported positive topline data from its Phase 1b trial of PIPE-791 for chronic pain in April 2026. The company reported its first-quarter 2026 financial results in May 2026. Daniel S. Lorrain, the Chief Scientific Officer, sold 4,170 shares of Class A Common Stock in May 2026. The company's stock increased by 212.68% from May 2, 2025, to April 30, 2026, and by 27.1% from the beginning of 2026 to May 8, 2026.

Contineum Therapeutics does not exhibit typical demand seasonality. The company's financial performance is primarily tied to the progress of its drug candidates through clinical trials, potential partnerships, regulatory approvals, and eventual commercialization.

Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule therapies for neuroscience, inflammation, and immunology indications. The company's pipeline includes PIPE-791 for IPF, PrMS, and chronic pain; PIPE-307 for RRMS and major depressive disorder; and CTX-343, a peripherally-restricted LPA1R antagonist.

Contineum Therapeutics is headquartered in San Diego, California, United States. While its corporate base is in the U.S., the company's clinical trials are conducted globally, with a primary market focus in the United States.

Contineum Therapeutics' brand reputation appears positive, driven by clinical development progress and strong stock performance. Positive topline data from the PIPE-791 Phase 1b trial in chronic pain and analyst ratings reflecting a "Moderate Buy" consensus contribute to this positive image. The substantial increase in stock price also indicates investor confidence.

Contineum Therapeutics has a notable institutional ownership presence, with 80 institutional owners and shareholders holding 29,547,190 shares. Major institutional owners include Suvretta Capital Management, Janus Henderson Group Plc, Ra Capital Management, Johnson & Johnson, Franklin Resources Inc, Balyasny Asset Management Llc, Perceptive Advisors Llc, Baker Bros. Advisors Lp, Vanguard Group Inc, and Millennium Management Llc. Daniel S. Lorrain, the Chief Scientific Officer, holds 143,542 shares directly and 6,842 shares indirectly through his spouse.